厚生労働省は2025年2月6日、薬事審議会プログラム医療機器調査会を開催。塩野義製薬の小児期における注意欠如・多動症（ADHD）の治療を補助するプログラム医療機器「ENDEAVORRIDE（エンデバーライド）」（一般名：注意欠如多動症治療補助プログラム）などの承認を了承した。また、プログラム医療機器に関する優先的な審査の対象品目の指定について審議され、塩野義製薬と、エクサウィザーズ100％子会社であるExaMD（東京・港、羽間康至代表取締役）がそれぞれ開発する2品目が指定された。2品目とも、認知症診断支援を目指すAI（人工知能）ソフトウエアだ。
Rigorous, dependable research has always been at the core of the American Heart Association (AHA) mission to be a relentless force for a world of…
Among patients with takotsubo syndrome (TTS), beta-blocker therapy was associated with lower follow-up mortality but not lower TTS recurrence, according to a study published Feb.…
This year’s report shows risk factors on the rise, enduring racial and geographic gaps, and clues to the global picture, too.
Nicotinamide Mononucleotide (NMN) has emerged as a popular supplement in the wellness and anti-aging communities, touted for its potential to boost cellular health, combat aging,…
Rigorous, dependable research has always been at the core of the American Heart Association (AHA) mission to be a relentless force for a world of…
Meeting Type: Live Meetings Location: Marriott Marquis Chicago, Chicago, IL Get a jump start on ACC.25 by attending Renal Denervation: The Hypertension Care Team Approach!…
American Heart Association scholarship and mentorship opportunities for students and leaders in fields such as health equity, health care and health sciences.
Rigorous, dependable research has always been at the core of the American Heart Association (AHA) mission to be a relentless force for a world of…
